Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Munoz-Martinez; Victor Sapena; Alejandro Forner; Jean-Charles Nault; Gonzalo Sapisochin; Lorenza Rimassa; Bruno Sangro; Jordi Bruix; Marco Sanduzzi-Zamparelli; Waclaw Holowko; Mohamed El Kassas; Tudor Mocan; Mohamed Bouattour; Philippe Merle; Frederik J. H. Hoogwater; Saleh A. Alqahtani; Helen L. Reeves; David J. Pinato; Emmanouil Giorgakis; Tim Meyer; Gerda Elisabeth Villadsen; Henning Wege; Massimiliano Salati; Beatriz Minguez; Giovan Giuseppe Di Costanzo; Christoph Roderburg; Frank Tacke; Maria Varela; Peter R. Galle; Mario Reis Alvares-da-Silva; Joerg Trojan; John Bridgewater; Giuseppe Cabibbo; Christian Toso; Anja Lachenmayer; Andrea Casadei-Gardini; Hidenori Toyoda; Tom Luedde; Rosanna Villani; Ana Maria Matilla Pena; Cassia Regina Guedes Leal; Monica Ronzoni; Manuel Delgado; Christie Perello; Sonia Pascual; Jose Luis Lledo; Josepmaria Argemi; Bristi Basu; Leonardo da Fonseca; Juan Acevedo

doi:10.1016/j.jhepr.2021.100260

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Munoz-Martinez, Victor Sapena, Alejandro Forner, Jean-Charles Nault, Gonzalo Sapisochin, Lorenza Rimassa, Bruno Sangro, Jordi Bruix, Marco Sanduzzi-Zamparelli, Waclaw Holowko, Mohamed El Kassas, Tudor Mocan, Mohamed Bouattour, Philippe Merle, Frederik J. H. Hoogwater, Saleh A. Alqahtani, Helen L. Reeves, David J. Pinato, Emmanouil Giorgakis, Tim MeyerGerda Elisabeth Villadsen, Henning Wege, Massimiliano Salati, Beatriz Minguez, Giovan Giuseppe Di Costanzo, Christoph Roderburg, Frank Tacke, Maria Varela, Peter R. Galle, Mario Reis Alvares-da-Silva, Joerg Trojan, John Bridgewater, Giuseppe Cabibbo, Christian Toso, Anja Lachenmayer, Andrea Casadei-Gardini, Hidenori Toyoda, Tom Luedde, Rosanna Villani, Ana Maria Matilla Pena, Cassia Regina Guedes Leal, Monica Ronzoni, Manuel Delgado, Christie Perello, Sonia Pascual, Jose Luis Lledo, Josepmaria Argemi, Bristi Basu, Leonardo da Fonseca, Juan Acevedo

Research output: Contribution to journal › Article › Academic › peer-review

24 Citations (Scopus)

14 Downloads (Pure)

Abstract

Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.

Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).

Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.

Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

Original language	English
Article number	100260
Number of pages	7
Journal	JHEP reports : innovation in hepatology
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/j.jhepr.2021.100260
Publication status	Published - Jun-2021

Keywords

COVID-19
Hepatocellular carcinoma
Cholangiocarcinoma
Liver cancer
Management
Clinical trials
Nurses
PROGRESSION-FREE SURVIVAL

Access to Document

10.1016/j.jhepr.2021.100260Licence: CC BY-NC-ND

Assessing the impact of COVID-19 on liver cancer management (CERO-19)Final publisher's version, 487 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

Munoz-Martinez, S., Sapena, V., Forner, A., Nault, J-C., Sapisochin, G., Rimassa, L., Sangro, B., Bruix, J., Sanduzzi-Zamparelli, M., Holowko, W., El Kassas, M., Mocan, T., Bouattour, M., Merle, P., Hoogwater, F. J. H., Alqahtani, S. A., Reeves, H. L., Pinato, D. J., Giorgakis, E., ... Acevedo, J. (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP reports : innovation in hepatology, 3(3), [100260]. https://doi.org/10.1016/j.jhepr.2021.100260

@article{e7e905a3490f49a8ad296b007cfe5809,

title = "Assessing the impact of COVID-19 on liver cancer management (CERO-19)",

abstract = "Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).",

keywords = "COVID-19, Hepatocellular carcinoma, Cholangiocarcinoma, Liver cancer, Management, Clinical trials, Nurses, PROGRESSION-FREE SURVIVAL",

author = "Sergio Munoz-Martinez and Victor Sapena and Alejandro Forner and Jean-Charles Nault and Gonzalo Sapisochin and Lorenza Rimassa and Bruno Sangro and Jordi Bruix and Marco Sanduzzi-Zamparelli and Waclaw Holowko and {El Kassas}, Mohamed and Tudor Mocan and Mohamed Bouattour and Philippe Merle and Hoogwater, {Frederik J. H.} and Alqahtani, {Saleh A.} and Reeves, {Helen L.} and Pinato, {David J.} and Emmanouil Giorgakis and Tim Meyer and Villadsen, {Gerda Elisabeth} and Henning Wege and Massimiliano Salati and Beatriz Minguez and {Di Costanzo}, {Giovan Giuseppe} and Christoph Roderburg and Frank Tacke and Maria Varela and Galle, {Peter R.} and Alvares-da-Silva, {Mario Reis} and Joerg Trojan and John Bridgewater and Giuseppe Cabibbo and Christian Toso and Anja Lachenmayer and Andrea Casadei-Gardini and Hidenori Toyoda and Tom Luedde and Rosanna Villani and {Matilla Pena}, {Ana Maria} and {Guedes Leal}, {Cassia Regina} and Monica Ronzoni and Manuel Delgado and Christie Perello and Sonia Pascual and {Luis Lledo}, Jose and Josepmaria Argemi and Bristi Basu and {da Fonseca}, Leonardo and Juan Acevedo",

year = "2021",

month = jun,

doi = "10.1016/j.jhepr.2021.100260",

language = "English",

volume = "3",

journal = "JHEP reports : innovation in hepatology",

issn = "2589-5559",

publisher = "Elsevier",

number = "3",

}

Munoz-Martinez, S, Sapena, V, Forner, A, Nault, J-C, Sapisochin, G, Rimassa, L, Sangro, B, Bruix, J, Sanduzzi-Zamparelli, M, Holowko, W, El Kassas, M, Mocan, T, Bouattour, M, Merle, P, Hoogwater, FJH, Alqahtani, SA, Reeves, HL, Pinato, DJ, Giorgakis, E, Meyer, T, Villadsen, GE, Wege, H, Salati, M, Minguez, B, Di Costanzo, GG, Roderburg, C, Tacke, F, Varela, M, Galle, PR, Alvares-da-Silva, MR, Trojan, J, Bridgewater, J, Cabibbo, G, Toso, C, Lachenmayer, A, Casadei-Gardini, A, Toyoda, H, Luedde, T, Villani, R, Matilla Pena, AM, Guedes Leal, CR, Ronzoni, M, Delgado, M, Perello, C, Pascual, S, Luis Lledo, J, Argemi, J, Basu, B, da Fonseca, L & Acevedo, J 2021, 'Assessing the impact of COVID-19 on liver cancer management (CERO-19)', JHEP reports : innovation in hepatology, vol. 3, no. 3, 100260. https://doi.org/10.1016/j.jhepr.2021.100260

TY - JOUR

T1 - Assessing the impact of COVID-19 on liver cancer management (CERO-19)

AU - Munoz-Martinez, Sergio

AU - Sapena, Victor

AU - Forner, Alejandro

AU - Nault, Jean-Charles

AU - Sapisochin, Gonzalo

AU - Rimassa, Lorenza

AU - Sangro, Bruno

AU - Bruix, Jordi

AU - Sanduzzi-Zamparelli, Marco

AU - Holowko, Waclaw

AU - El Kassas, Mohamed

AU - Mocan, Tudor

AU - Bouattour, Mohamed

AU - Merle, Philippe

AU - Hoogwater, Frederik J. H.

AU - Alqahtani, Saleh A.

AU - Reeves, Helen L.

AU - Pinato, David J.

AU - Giorgakis, Emmanouil

AU - Meyer, Tim

AU - Villadsen, Gerda Elisabeth

AU - Wege, Henning

AU - Salati, Massimiliano

AU - Minguez, Beatriz

AU - Di Costanzo, Giovan Giuseppe

AU - Roderburg, Christoph

AU - Tacke, Frank

AU - Varela, Maria

AU - Galle, Peter R.

AU - Alvares-da-Silva, Mario Reis

AU - Trojan, Joerg

AU - Bridgewater, John

AU - Cabibbo, Giuseppe

AU - Toso, Christian

AU - Lachenmayer, Anja

AU - Casadei-Gardini, Andrea

AU - Toyoda, Hidenori

AU - Luedde, Tom

AU - Villani, Rosanna

AU - Matilla Pena, Ana Maria

AU - Guedes Leal, Cassia Regina

AU - Ronzoni, Monica

AU - Delgado, Manuel

AU - Perello, Christie

AU - Pascual, Sonia

AU - Luis Lledo, Jose

AU - Argemi, Josepmaria

AU - Basu, Bristi

AU - da Fonseca, Leonardo

AU - Acevedo, Juan

PY - 2021/6

Y1 - 2021/6

N2 - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

AB - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).

KW - COVID-19

KW - Hepatocellular carcinoma

KW - Cholangiocarcinoma

KW - Liver cancer

KW - Management

KW - Clinical trials

KW - Nurses

KW - PROGRESSION-FREE SURVIVAL

U2 - 10.1016/j.jhepr.2021.100260

DO - 10.1016/j.jhepr.2021.100260

M3 - Article

VL - 3

JO - JHEP reports : innovation in hepatology

JF - JHEP reports : innovation in hepatology

SN - 2589-5559

IS - 3

M1 - 100260

ER -